Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Cost-effectiveness of monoclonal antibody evaluated for metastatic breast cancer
August 15th, 2005
A model-based cost-effectiveness analysis was conducted for a monoclonal antibody against HER-2 (Trastuzumab) for metastatic breast cancer. "The aim of this study was to evaluate the cost-effectiveness of trastuzumab in patients with metastatic breast cancer (MBC) in a model-based cost-effectiveness analysis (CEA). Trastuzumab has shown considerable activity in patients with MBC that over express HER2," researchers in Norway reported. "However, significant resources have been allocated to finance this new therapy. Due to ever increasing pressures on healthcare budgets, economic evaluations are requested in order to compare health effects with costs....
Source: Pharma Business Week (2005-08-15)
|
